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NK cells are crucial components of the innate immune system due to their capacity to 
exert rapid cytotoxic and immunomodulatory function in the absence of prior sensiti-
zation. NK cells can become activated by exposure to target cells and/or by cytokines 
produced by antigen-presenting cells. In this study, we examined the effects of a simian 
immunodeficiency virus (SIV) vaccine regimen and subsequent SIV infection on the 
cytotoxic and immunomodulatory functions of circulatory NK cells. While vaccination did 
not significantly impact the capacity of NK cells to kill MHC-devoid 721.221 target cells, 
SIV-infection led to a significant decrease in target cell killing. NK cells from uninfected 
macaques were responsive to a low dose (5 ng/ml) of IL-15 pre-activation, leading to 
significant increases in their cytotoxic potential, however, NK cells from SIV-infected 
macaques required a higher dose (50 ng/ml) of IL-15 pre-activation in order to signifi-
cantly increase their cytotoxic potential. By contrast, no differences were observed in the 
capacity of NK cells from vaccinated and SIV-infected macaques to respond to IL-12 and 
IL-18. Similarly, NK cells both before and after infection exhibited equivalent responses 
to Fc-mediated activation. Collectively, our results show that early SIV-infection impairs 
the natural cytotoxic capacity of circulatory NK cells without affecting Fc-mediated or 
cytokine-producing function.
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inTrODUcTiOn
NK cells participate in early control of viral infection through their capacity to exert rapid cytolytic 
and immunoregulatory functions (1). Their functional activity is tightly controlled by the balance 
of inhibitory and activatory signals engaged via various cell surface receptors (2, 3). Differential 
expression of these inhibitory and activatory receptors gives rise to NK cell heterogeneity and allows 
NK cells to respond to various stimuli (4). During antiviral immune responses, NK cells can receive 
activatory signals through different types of toll-like receptors (TLR) and activatory killer-cell 
immunoglobulin-like receptors (KIRs) (5). Importantly, chronic viral infections have been shown 
to affect NK cell maturation at different stages and to promote the expansion of functionally impaired 
subpopulations (6). Specifically for human immunodeficiency virus (HIV) infection, viremia has 
been correlated with an expansion of CD16+ NK cells that exhibit anergy and decreased cytotoxic 
potential (7–9).
Rhesus macaques (Macaca mulattta) are the animal model of choice for evaluating novel HIV 
vaccine and therapeutic candidates through the use of the simian immunodeficiency virus (SIV) (10). 
TaBle 1 | summary of immunization regimen of macaques used in this study.
immunization group Weeks 0 and 4 (iM) Week 12 (iT) Weeks 24 and 36 (iM) Week 48 (ir)
1. DNA (n = 7) DNA-SIVa plasmids + control DNA Ad5hr-SIVb recombinants SIV proteinsc SIVmac251d
2. DNA/IL-12 (n = 7) DNA-SIV plasmids + DNA/IL-12 Ad5hr-SIV recombinants SIV proteins SIVmac251
3. DNA/IL-15 (n = 7) DNA–SIV plasmids + DNA/IL-15 Ad5hr-SIV recombinants SIV proteins SIVmac251
aThree DNA-SIV plasmids separately encoding SIVmac239env, SIVmac239gag, and SIVmac239rev/nef were administered together by the indicated route at 2.5 mg of DNA per dose. IM, 
intramuscular.
bThree Ad5hr-SIV recombinants separately encoding SIVsmH4 env/rev; SIVmac239 gag; and SIVmac239 nefΔ1–13 were administered at 5 × 108 pfu/recombinant/route. IT, intratracheal.
cSIVmac251 gp140; and SIVmac239 Nef proteins were given at a dose of 100 and 50 μg, respectively, in MPL-SE adjuvant.
dChallenge administered at 10 50% monkey infectious doses. IR, intrarectal.
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As in humans, macaque circulatory NK cells can be divided into 
subsets based on their cell surface expression levels of CD16 and 
CD56. CD16+ NK cells comprise the major circulatory subset 
(~90%) and contain higher amounts of cytoplasmic granules rich 
in cytotoxic proteins. Moreover, CD16+ NK cells are capable of 
performing antibody-dependent NK cell responses. CD56+ NK 
cells are a smaller (~1–5%) immunoregulatory subset that is 
specialized in cytokine production. Unique to rhesus macaques, 
CD16−CD56− double-negative NK cells represent 5–10% of 
circulatory NK cells and are capable of both cytotoxic and immu-
noregulatory functions (11–13). Similar to human HIV infection, 
SIV infection in macaques leads to an increase in the number of 
circulatory and LN-resident CD16+ NK cells (14, 15). Interestingly, 
LN-resident CD16+ NK cells from SIV-infected macaques 
displayed increased perforin expression and cytotoxicity (15). 
Although several studies in human HIV infection have evaluated 
the impact of vaccination and virus replication on the distribu-
tion and functional status of human NK cells, only a few studies 
have focused on vaccinated and SIV-infected rhesus macaques 
(16). For these reasons, in the present study, we examined the NK 
cell cytotoxic potential and functionality of circulatory NK cells 
in rhesus macaques vaccinated sequentially with SIV-specific 
DNA, replication-competent adenoviral recombinants, and 
SIV proteins, prior to and after SIV infection. Our results show 
that while vaccination did not significantly impact the cytotoxic 
potential of circulatory NK cells, SIV infection significantly 
reduced the cytotoxic capacity of these cells. Furthermore, SIV 
infection also increased the IL-15 stimulation threshold required 
to significantly improve NK cell cytotoxicity when compared with 
uninfected and vaccinated macaques. Similarly, we also evaluated 
the impact of vaccination and SIV infection on Fc- and cytokine-
mediated NK cell effector responses. Interestingly, NK cells from 
vaccinated and SIV-infected macaques displayed similar response 
levels to both types of stimulation. Collectively, our findings show 
that early set point SIV viremia significantly impairs the cytotoxic 
potential of circulatory NK cells.
MaTerials anD MeThODs
animals, immunization, siV challenge, 
and sample collection
Assays used viably frozen peripheral blood mononuclear cells 
(PBMCs) obtained from eight rhesus macaques enrolled in a 
previous vaccine study (17). As shown in Table  1, macaques 
from this previous study were primed twice with multigenic 
SIV plasmid DNA with or without IL-12 DNA or IL-15 DNA at 
weeks 0 and 4. Next, macaques received a single dose of Ad5hr-
SIV recombinants at week 12 and were further boosted with 
SIV proteins in MPL-SE adjuvant at weeks 24 and 36. Finally, 
macaques were challenged intrarectally with 10 50% monkey 
infectious doses of SIVmac251. Animals were housed at Advanced 
BioScience Laboratories, Inc. (ABL, Kensington, MD, USA) 
and maintained according to institutional Animal Care and Use 
Committee guidelines and the NIH Guide for the Care and Use 
of Laboratory Animals. Blood samples were collected by veni-
puncture of anesthetized animals and PBMCs were obtained by 
centrifugation on Ficoll-Paque PLUS gradients (GE Healthcare, 
Piscataway, NJ, USA). PBMCs were frozen in 90% fetal bovine 
serum (Invitrogen, Carlsbad, CA, USA), 10% dimethyl sulfox-
ide (Sigma-Aldrich, St. Louis, MO, USA) and stored in liquid 
nitrogen until use. Upon thawing, good cellular viability (>85% 
live cells) with trypan blue viability dye was observed. Cells were 
washed and re-suspended in R-10 medium (RPMI 1640 contain-
ing 10% FBS, 2 mM l-glutamine, 1% non-essential amino acids, 
1% sodium pyruvate, and antibiotics).
721.221 cell Killing assays
To evaluate the cytotoxic potential of circulatory NK cells, a 
flow cytometry-based killing assay was used. 721.221 target 
cells, which lack MHC-Class I, were fluorescently labeled with 
2.5  μM PKH-26 red labeling (Sigma-Aldrich) and 2.5  μM 
CFDA-SE (Molecular Probes, Carlsbad, CA, USA) in order to 
separate them from non-fluorescent effector cells. Target cells 
were washed twice and plated in R-10 medium at a final concen-
tration of 10,000 per well in V-bottom 96-well plates. Effector 
PBMCs were thawed a day prior to running the assays and cul-
tured in media alone or in the presence of recombinant rhesus 
IL-15 (NIH/NCRR Resource for Non-human Primate Immune 
Reagents, Atlanta, GA, USA). After incubation, effector PBMCs 
were washed and then added at the indicated effector-to-target 
(E:T) ratios to a final volume of 200 μl. Plates were incubated 
at 37°C for 4 h. After incubation, cells were labeled with 0.5 μl 
of aqua LIVE/DEAD viability dye (Invitrogen) in 100 μl PBS 
per well. Plates were washed twice with PBS and finally re-
suspended in 200 μl of a 2% PBS–paraformaldehyde solution. 
Plates were stored at 4°C until acquisition on a LSRII machine 
equipped with a high throughput system (BD Biosciences, San 
Jose, CA, USA). Specific killing was measured by incorporation 
of the Aqua LIVE/DEAD viability dye in CFSE+PKH+ target 
cells. Target cells cultured in the absence of effector cells were 
FigUre 1 | immune cell subsets and viral load status of macaque samples used in the present study. Frozen PBMCs from previously vaccinated and 
SIVmac251-challenged macaques were thawed and stained with fluorochrome-conjugated monoclonal antibodies. (a) Gating strategy used to identify the proportional 
abundance of B cells, NK cells, and CD4+ and CD8+ T cells in samples. (B) Distribution of these immune subsets before vaccination (Pre), during vaccination (weeks 
14 and 38) and 8–12 weeks after SIVmac251 intrarectal challenge (post-challenge) as determined by flow cytometry. Data are shown as minimum to maximum boxes 
with all data points represented. (c) Post-challenge viral loads in the eight macaques were used in the present study. Viral load data were taken from the previous 
report of Demberg et al. (17), and Vaccination group (described in Table 1) for each macaque is indicated in parenthesis.
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used as negative controls to correct for background levels of 
dead cells.
nK cell stimulation assays
NK cells were activated using either cytokines, Fc-receptor 
crosslinking or by co-culture with NK-sensitive 721.221 target 
cells. PBMCs (1–1.5 ×  106) were stimulated in 0.5  ml of R-10 
medium in 5  ml Flow Cytometry tubes. Cytokine stimula-
tions were done for 24  h with the indicated concentrations of 
recombinant macaque IL-15 and IL-18 (both from the NIH/
NCRR Resource for Non-human Primate Immune Reagents), 
and recombinant human IL-12p70 (Peprotech, Rocky Hill, NJ, 
USA). Fc-receptor crosslinking and 721.221 cell stimulation 
were performed for 6 h by adding 4 μl of an APC-Cy7 anti-CD16 
antibody (BD Biosciences) or 721.221 cells at a 5:1 E:T ratio, 
respectively. NK cell activation by crosslinking of CD16 surface 
receptors using fluorochrome-conjugated anti-CD16 antibodies 
was performed, as previously described (18). A fluorochrome-
matched isotype control antibody was used as a negative control. 
PMA/Ionomycin (eBioscience, San Diego, CA, USA) was used as 
a positive control. In all stimulation conditions, BD GolgiPlug, 
BD GolgiStop, and an Alexa Fluor 647 anti-CD107a antibody 
(eBioscience) were added at the manufacturer’s recommended 
concentrations for the last 5 h of culture. Cells were subsequently 
washed and the expression levels of CD107a and IFN-γ were 
measured by Flow Cytometry. Background levels of CD107a and 
IFN-γ expression by non-stimulated PBMCs were subtracted 
from specific responses.
Flow cytometry antibodies
Anti-human fluorochrome-conjugated monoclonal antibodies 
known to cross-react with rhesus macaque antigens were used, 
including FITC anti-CD20 (2H7), APC-Cy7 anti-CD16 (3G8), 
V450 anti-IFN-γ (B27), Alexa Fluor 700 anti-CD3 (SP34-2), 
and PerCP-Cy5.5 anti-CD8 (SK1), all from BD Biosciences; 
eFluor 660 anti-CD107a (eBioH4A3) from eBioscience; PE 
anti-NKG2A (Z199) from Beckman Coulter (Fullerton, CA, 
USA); QDot605 anti-CD8 (3B5), and the Yellow and Aqua Live/
Dead viability dyes from Invitrogen; and QDot605 anti-CD4 
(19Thy-5D7) from the NIH Non-human Primate Reagent 
Resource (Boston, MA, USA). Cells were stained for specific 
surface molecules, fixed and permeabilized with a Cytofix/
Cytoperm Kit (BD Biosciences), and then stained for specific 
intracellular molecules. At least 250,000 singlet events (PBMCs) 
were acquired on a LSR II (BD Biosciences) and analyzed using 
FlowJo Software (Treestar Inc., Ashland, OR, USA). For all 
samples, gating was established using a combination of isotype 
and fluorescence-minus-one controls.
FigUre 2 | siV infection impairs natural cytotoxic capacity of rhesus macaque circulatory nK cells. Frozen PBMCs were thawed and cultured overnight 
in media alone or in media supplemented with 5 ng/ml of recombinant rhesus macaque IL-15. PBMCs were then co-cultured with CFSE/PKH double-labeled 
721.221 target cells at different effector-to-target cell ratios for 4 h. (a) Gating strategy used to differentiate 721.221 target cells (CFSE+PKH+) from unlabeled 
effector cells. (B) Killing of CFSE+PKH+ target cells as measured by the incorporation of the aqua amine-reactive dye. (c,D) 721.221 target cell killing by PBMCs 
from vaccination (c) and post-challenge (D) time-points as compared with PBMCs obtained pre-vaccination (Pre). Effector cells used in C and D were rested 
overnight in media alone. Data reported are means ± SEM. *p < 0.05 indicates statistically significant differences between the indicated killing curves as determined 
by two-way ANOVA.
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statistical analysis
Data were analyzed as described in figure legends using Prism 
(v6.01, GraphPad Software). A p value ≤0.05 was considered 
statistically significant.
resUlTs
immunological and Virological 
characteristics of samples Used  
in This study
In this study, we investigated the effects of vaccination and 
SIV infection on the functionality of circulatory NK cells 
(CD3−CD8+NKG2A+ lymphocytes). Samples used here had 
been viably frozen as part of a previous vaccination study (17). 
Although no protection from acquisition was observed in the 
previous study, samples were available from different time-points 
before and after challenge (pre-immunization, 14 and 38 weeks 
post-vaccination, and 8 and 12 weeks post-challenge). Table 1 
describes the components of each vaccination group. Given 
that in the prior study, there were no observed differences in 
cellular or humoral immune responses between animals in 
each vaccination group (17), we combined available samples 
from vaccinated animals into a single group. Upon thawing 
of each frozen PBMC sample, immune cell composition was 
FigUre 3 | low dose of il-15 pre-treatment does not improve cytotoxic potential of nK cells from siV-infected macaques. Frozen PBMCs were 
thawed and cultured overnight in media alone or in media supplemented with 5 ng/ml of recombinant rhesus macaque IL-15 before being used in 721.221 killing 
assays. (a,B) Comparison of killing by PBMCs from pre-vaccination (a) and post-challenge (B) time-points. Data reported are means ± SEM. **p < 0.01 indicates 
statistically significant differences between the indicated killing curves as determined by two-way ANOVA. (c,D) Impact of IL-15 pre-treatment on each type of 
effector cell at either a high [50:1 (c)] or a low [3.13:1 (D)] effector-to-target cell ratio. For these assays, six pre-vaccination samples were available and nine 
post-challenge samples were available (both weeks 8 and 12 post-challenge samples from macaque 393 were available). *p < 0.05 indicates statistically significant 
differences between the two compared conditions as determined by Wilcoxon matched-pairs signed-rank test. n.s., not significant.
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evaluated by measuring the proportional abundance of CD4 
(CD3+CD4+), CD8 (CD3+CD8+), B (CD3−CD20+), and NK cells 
(CD3−CD8+NKG2A+) by flow cytometry (Figure 1A). As shown 
in Figure 1B, no significant changes in immune cell composition 
were observed in samples during vaccination or after infection. 
Figure 1C shows the plasma viral loads post-challenge for the 
eight PBMC samples used in the present study. To increase the 
sample size post-SIV challenge, samples from weeks 8 and 12 
post-challenge time-points were combined into a single post-
challenge group.
nK cells from siV-infected Macaques are 
less effective at Mediating Direct 
cytotoxic Function
In order to assess if vaccination or SIV infection had an 
effect on NK cell function, we first evaluated the capacity of 
circulatory NK cells to mediate natural cytotoxicity against 
MCH-1-devoid 721.221 cells. For this, we adapted a previously 
used flow cytometry-based killing assay and double-labeled 
721.221 target cells with CFSE and PKH (Figure  2A) (13). 
This 721.221 cell killing assay allowed us to evaluate the 
cytotoxic potential of NK cells that had been incubated in the 
presence or absence of exogenous IL-15 at different target-to-
effector cell ratios (Figure  2B). As shown in Figure  2C, no 
significant differences were observed in the cytotoxic capacity 
of NK cells in vaccinated macaques when compared with 
pre-immunization samples. On the other hand, we observed a 
significant reduction in NK cell cytotoxic function when pre-
immunization samples were compared with post-challenge 
samples (Figure 2D).
high Doses of il-15 Pre-activation are 
required to rescue cytotoxic Function in 
nK cells from siV-infected Macaques
Given that SIV infection impairs the natural cytotoxic potential 
of circulatory NK cells, we sought to determine if exogenous 
FigUre 4 | higher dose of il-15 pre-treatment is required to improve 
cytotoxic potential of nK cells from siV-infected macaques. Frozen 
PBMCs obtained from six macaques at 8 or 12 weeks post-challenge were 
thawed and cultured overnight in media alone or in media supplemented with 
50 ng/ml of recombinant rhesus macaque IL-15 before being used in 
721.221 killing assays. (a) Killing of 721.221 target cells by PBMCs from 
SIV-infected macaques pre-cultured with or without 50 ng/ml of IL-15. Data 
reported are means ± SEM. **p < 0.01 indicates statistically significant 
differences between the indicated killing curves as determined by two-way 
ANOVA. (B,c) Impact of 50 ng/ml IL-15 pre-treatment on 721.221 target cell 
killing at either a high [50:1 (B)] or low [3.13:1 (c)] effector-to-target cell ratio. 
*p < 0.05 indicates statistically significant differences between the two 
compared conditions as determined by Wilcoxon matched-pairs signed-rank 
test.
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IL-15 pre-activation was able to reverse this impairment. To 
this end, we pre-activated PBMCs with 5  ng/ml of IL-15 for 
18  h prior to their use. As shown in Figure  3A, IL-15 pre-
activation at 5  ng/ml significantly increased the cytotoxic 
capacity of NK cells from uninfected macaques. On the other 
hand, pre-activation with 5 ng/ml of IL-15 did not improve the 
cytotoxic potential of NK cells from SIV-infected macaques 
(Figure 3B). The lack of responsiveness to IL-15 observed on 
NK cells from SIV-infected macaques was observed both at high 
(50:1, Figure 3C) and low (3.13:1, Figure 3D) E:T ratios. Next, 
we evaluated if a higher dose of IL-15 is needed to efficiently 
activate the cytotoxic potential of NK cells from SIV-infected 
macaques. For this purpose, we pre-activated PBMCs from SIV-
infected macaques with 50 ng/ml of IL-15 prior to evaluating 
cytotoxic potential. As shown in Figure 4A, 50 ng/ml of IL-15 
significantly increased the cytotoxic potential of circulatory NK 
cells from SIV-infected macaques. The improvement in cyto-
toxic potential observed by pre-incubating cells with 50 ng/ml 
of IL-15 was significant both at high (50:1, Figure 4B) and low 
(3.13:1, Figure 4C) E:T ratios.
Vaccination Does not affect the cytotoxic 
and cytokine-Producing Function of nK 
cells
Having observed that SIV infection leads to an impairment 
in the killing capacity of circulatory NK cells, as measured by 
direct killing of MHC-I-devoid target cells, we evaluated the 
activation profile of circulatory NK cells in response to differ-
ent cytotoxic and cytokine-producing stimulations. Surface 
expression of CD107a (LAMP-1) is a commonly used surrogate 
marker for cell degranulation and cytotoxicity (19). Stimulation 
of circulatory NK cells through CD16 crosslinking (α-CD16) or 
co-culture with 721.221 cells leads to NK cell degranulation and 
surface expression of CD107a (Figure  5A). When compared 
with pre-vaccination levels, a trend toward increased CD107a 
expression was observed at week 38 (end of vaccination proto-
col). This was observed both in response to CD16 crosslinking 
and 721.221 cell co-culture, but not in response to non-specific 
activation with PMA plus Ionomycin (Figure 5B). Given that 
CD16 crosslinking and 721.221 cell co-culture also upregulate 
IFN-γ production, we also evaluated this parameter in vac-
cinated and SIV-infected macaques. Although only minimal 
IFN-γ production was observed after CD16 crosslinking in both 
vaccinated and SIV-infected macaques, 721.221 cell co-culture 
induced detectable levels of IFN-γ (Figure  5C). A significant 
decrease in the production of IFN-γ by circulatory NK cells 
was observed when comparing samples from week 14 (after 
adenovirus vaccination) with post-infection (Figure  5C). No 
significant differences in IFN-γ production at any time-point 
were detected when stimulated with PMA plus Ionomycin 
(Figure 5C).
Given that NK cells can modulate the adaptive immune 
response by activating or inhibiting T cell responses (20), and 
due to their potential to rapidly respond to virus infection 
(21), we evaluated the capacity of circulatory NK cells from 
vaccinated and SIV-infected macaques to respond to different 
exogenous cytokine stimuli. We were particularly interested 
in responses to IL-15 stimulation given its pleiotropic effects 
and the major role played during inflammatory and protective 
immune responses (22). Interestingly, when directly stimulating 
circulatory NK cells with increasing concentrations of IL-15, we 
observed increased CD107a expression on week 38 samples 
(Figure  6A). These responses lacked statistically significance 
likely due to the small number of animals assayed. Other 
antigen-presenting cell-derived cytokines that play an important 
role in NK cell effector function are IL-12 and IL-18 (23, 24). 
To determine if circulatory NK cells from vaccinated and SIV-
infected macaques have increased or reduced responsiveness to 
IL-12 and IL-18 stimulation, we performed stimulation assays 
with these two cytokines in the presence or absence of a low 
(1 ng/ml) IL-15 dose. When measuring CD107a expression, a 
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trend toward increased expression was observed in response to 
IL-12 stimulation on week 38 and post-challenge samples only 
in the presence of IL-15 (Figure 6B). A similar trend, although 
independent of IL-15 addition, was observed after IL-18 
stimulation (Figure 6C). Differently from CD107a expression, 
IFN-γ production was not significantly increased by IL-15, 
IL-12, or IL-18 in any of the concentrations and combinations 
tested (Figures 6D–F). It is important to mention that, in the 
present study, we did not evaluate NK cell functional responses 
in a subset-specific manner and, thus, the lack of responsiveness 
observed may be related to changes in the relative frequencies 
of NK cell subsets.
FigUre 5 | nK cell cytotoxic responses through vaccination and after siV infection. Frozen PBMCs obtained over the course of vaccination and challenge 
were thawed, cultured overnight, and then stimulated for 5 h with anti-CD16 antibody, 721.221 cells (5:1 effector-to-target cell ratio) or PMA plus ionomycin.  
(a) Representative flow cytometry dot plots displaying the proportional abundance of CD107a+ cells within total NK cells (CD3−CD8+NKG2A+) for each stimulatory 
condition. (B,c) Expression of CD107a (B) and production of IFN-γ (c) by total NK cells in response to each stimulation was quantified at the indicated time-points. 
Values of non-stimulated samples and negative controls have been subtracted. Data are shown as minimum to maximum boxes with all data points represented. 
*p < 0.05 indicates statistically significant differences between the indicated time-points by Mann–Whitney test.
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FigUre 6 | nK cell cytokine-dependent responses through vaccination and after siV infection. Frozen PBMCs obtained over the course of vaccination 
and challenge were thawed and stimulated overnight in the presence of different concentrations and combinations of IL-15, IL-12, and IL-18. (a–F) Expression of 
CD107a (top row) or IFN-γ (bottom row) by total NK cells in response to high (50 ng/ml) and low (5 ng/ml) concentrations of IL-15 (a,D); a high (250 ng/ml) dose of 
IL-12 in the presence (+) or absence (−) of a low (5 ng/ml) dose of IL-15 (B,e); and a high (250 ng/ml) dose of IL-18 in the presence (+) or absence (−) of a low 
(5 ng/ml) dose of IL-15 (c,F). Values of non-stimulated samples and negative controls have been subtracted. Data are shown as minimum to maximum boxes with 
all data points represented.
DiscUssiOn
NK cell effector function becomes impaired during HIV and 
SIV infection (3). By taking advantage of viably frozen PBMC 
samples from a previous vaccination and challenge study (17), we 
observed that circulatory NK cells from SIV-infected macaques 
displayed decreased cytotoxicity. Moreover, NK cells from SIV-
infected animals also required higher levels of IL-15 pre-stimu-
lation in order to restore their natural cytotoxic potential. There 
has been disagreement in the literature on how HIV affects NK 
cell functionality. Some previous studies reported that viremic 
HIV-1 infection negatively impacts the cytolytic abilities of NK 
cells (25, 26), while others have shown that HIV elevates NK cell 
activity despite a reduction in cell number (27). Other studies 
have shown that NK cells from HIV-1 infected donors are able 
to form normal lytic conjugates with target cells; however, their 
ability to mediate lysis is inhibited (28). Similarly, the frequency 
of effector-to-target conjugates observed in HIV-1 patients is 
comparable to those observed in healthy controls (29).
Impairment of NK cell cytotoxicity can be caused by a 
change in surface expression of natural cytotoxicity receptors 
(NCRs). The expression of activatory NCRs, such as NKp46, 
NKp30, and NKp44, is known to be decreased among viremic 
patients. This defective NCR expression has been associated with 
a similar decrease in NK killing of different tumor target cells 
(30). IL-15 and IL-15 +  sIL-15Rα conjugates have previously 
been shown to improve the cytotoxic potential of NK cells in 
various viral and neoplastic environments (31, 32). Particularly, 
long-term culture of NK cells in the presence of IL-15 and cells 
co-expressing IL-15Rα and 4-1BBL ligand (CD137L) has been 
shown to increase KIR, NKG2D, and NCR expression levels, 
thus improving cytotoxicity (33). It is plausible that overnight 
pre-activation of NK cells from SIV-infected rhesus macaques 
in high IL-15 concentrations similarly leads to a restoration 
of NCR surface expression and, therefore, partially improves 
natural cytotoxicity. Given that NCR expression in NK cells 
can be differentially regulated by cytokines (34), it would be of 
interest to evaluate the potential of other common-gamma chain 
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